130 related articles for article (PubMed ID: 22903532)
1. A reversal in the vascularity of metastatic liver tumors from colorectal cancer after the cessation of chemotherapy plus bevacizumab: contrast-enhanced ultrasonography and histological examination.
Kitamura H; Koike S; Nakazawa K; Matsumura H; Yokoi K; Nakagawa K; Arai M
J Surg Oncol; 2013 Feb; 107(2):155-9. PubMed ID: 22903532
[TBL] [Abstract][Full Text] [Related]
2. Correlation between response to chemotherapy with concomitant bevacizumab for hepatic metastasis of colorectal cancer and degree of enhancement using contrast-enhanced computed tomography.
Osawa G; Yoshimatsu K; Yokomizo H; Okayama S; Sagawa M; Naritaka Y
Cancer Chemother Pharmacol; 2013 Jul; 72(1):209-15. PubMed ID: 23670642
[TBL] [Abstract][Full Text] [Related]
3. Fate of metastatic foci after chemotherapy and usefulness of contrast-enhanced intraoperative ultrasonography to detect minute hepatic lesions.
Uetake H; Tanaka S; Ishikawa T; Sugihara K; Arii S
J Hepatobiliary Pancreat Sci; 2012 Sep; 19(5):509-14. PubMed ID: 22539087
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases.
Klinger M; Eipeldauer S; Hacker S; Herberger B; Tamandl D; Dorfmeister M; Koelblinger C; Gruenberger B; Gruenberger T
Eur J Surg Oncol; 2009 May; 35(5):515-20. PubMed ID: 19200687
[TBL] [Abstract][Full Text] [Related]
5. Longitudinal analysis of organ-specific tumor lesion sizes in metastatic colorectal cancer patients receiving first line standard chemotherapy in combination with anti-angiogenic treatment.
Mercier F; Kerioui M; Desmée S; Guedj J; Krieter O; Bruno R
J Pharmacokinet Pharmacodyn; 2020 Dec; 47(6):613-625. PubMed ID: 32865652
[TBL] [Abstract][Full Text] [Related]
6. Pathologic complete response to neoadjuvant FOLFOX in combination with bevacizumab in unresectable metastatic colorectal carcinoma.
Duffy A; Shia J; Huitzil-Melendez FD; Fong Y; O'Reilly EM
Clin Colorectal Cancer; 2008 Mar; 7(2):140-3. PubMed ID: 18501074
[TBL] [Abstract][Full Text] [Related]
7. Preoperative chemotherapy and the risk of hepatotoxicity and morbidity after liver resection for metastatic colorectal cancer: a single institution experience.
Wolf PS; Park JO; Bao F; Allen PJ; DeMatteo RP; Fong Y; Jarnagin WR; Kingham TP; Gönen M; Kemeny N; Shia J; D'Angelica MI
J Am Coll Surg; 2013 Jan; 216(1):41-9. PubMed ID: 23041049
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy After Immunotherapy: Response Rescue in a Patient With Microsatellite Instability-high Colorectal Cancer Post-Pembrolizumab.
Das S; Allen A; Berlin J
Clin Colorectal Cancer; 2020 Jun; 19(2):137-140. PubMed ID: 32146081
[TBL] [Abstract][Full Text] [Related]
9. Recurrent disease four years after surgery and adjuvant chemotherapy.
Pozzo C; Barone C
Cancer Treat Rev; 2008; 34 Suppl 2():S8-11. PubMed ID: 19101406
[TBL] [Abstract][Full Text] [Related]
10. Conversion to complete resection with mFOLFOX6 with bevacizumab or cetuximab based on K-ras status for unresectable colorectal liver metastasis (BECK study).
Hatano E; Okuno M; Nakamura K; Ishii T; Seo S; Taura K; Yasuchika K; Yazawa T; Zaima M; Kanazawa A; Terajima H; Kaihara S; Adachi Y; Inoue N; Furumoto K; Manaka D; Tokka A; Furuyama H; Doi K; Hirose T; Horimatsu T; Hasegawa S; Matsumoto S; Sakai Y; Uemoto S
J Hepatobiliary Pancreat Sci; 2015 Aug; 22(8):634-45. PubMed ID: 25926024
[TBL] [Abstract][Full Text] [Related]
11. Preoperative Chemotherapy with Bevacizumab Extends Disease-free Survival After Resection of Liver Metastases from Colorectal Cancer.
Umehara M; Umehara Y; Takahashi K; Murata A; Nishikawa S; Tokura T; Matsuzaka M; Tanaka R; Morita T
Anticancer Res; 2016 Apr; 36(4):1949-54. PubMed ID: 27069185
[TBL] [Abstract][Full Text] [Related]
12. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
Hegewisch-Becker S; Graeven U; Lerchenmüller CA; Killing B; Depenbusch R; Steffens CC; Al-Batran SE; Lange T; Dietrich G; Stoehlmacher J; Tannapfel A; Reinacher-Schick A; Quidde J; Trarbach T; Hinke A; Schmoll HJ; Arnold D
Lancet Oncol; 2015 Oct; 16(13):1355-69. PubMed ID: 26361971
[TBL] [Abstract][Full Text] [Related]
13. Improved first-line chemotherapy: a better chance for surgery?
Tejpar S; Van Cutsem E; Adam R
Lancet Oncol; 2010 Jan; 11(1):4-5. PubMed ID: 19942480
[No Abstract] [Full Text] [Related]
14. Reversal of attachment to or invasion of major intrahepatic vessels by colorectal liver metastases according to prehepatectomy chemotherapy regimen.
Tanaka K; Nakagawa K; Yabushita Y; Hiroshima Y; Matsuo K; Ota M; Ichikawa Y; Taguri M; Tanabe M; Koda K; Endo I
Surgery; 2014 May; 155(5):936-44. PubMed ID: 24656858
[TBL] [Abstract][Full Text] [Related]
15. Complete calcification of colorectal liver metastases on imaging after chemotherapy does not indicate sterilization of disease.
Goyer P; Benoist S; Julié C; Hajjam ME; Penna C; Nordlinger B
J Visc Surg; 2012 Aug; 149(4):e271-4. PubMed ID: 22633572
[TBL] [Abstract][Full Text] [Related]
16. Liver resection for metastatic colorectal cancer in the age of neoadjuvant chemotherapy and bevacizumab.
Yoo PS; Lopez-Soler RI; Longo WE; Cha CH
Clin Colorectal Cancer; 2006 Sep; 6(3):202-7. PubMed ID: 17026789
[TBL] [Abstract][Full Text] [Related]
17. [Hepatic resection after systemic chemotherapy for liver metastasis of colorectal cancer].
Nishigaki T; Ide Y; Murata K
Gan To Kagaku Ryoho; 2010 Nov; 37(12):2566-8. PubMed ID: 21224641
[TBL] [Abstract][Full Text] [Related]
18. Splenic volume may be a useful indicator of the protective effect of bevacizumab against oxaliplatin-induced hepatic sinusoidal obstruction syndrome.
Imai K; Emi Y; Iyama KI; Beppu T; Ogata Y; Kakeji Y; Samura H; Oki E; Akagi Y; Maehara Y; Baba H;
Eur J Surg Oncol; 2014 May; 40(5):559-566. PubMed ID: 24388740
[TBL] [Abstract][Full Text] [Related]
19. Usefulness of contrast-enhanced intraoperative ultrasound in identifying disappearing liver metastases from colorectal carcinoma after chemotherapy.
Arita J; Ono Y; Takahashi M; Inoue Y; Takahashi Y; Saiura A
Ann Surg Oncol; 2014 Jun; 21 Suppl 3():S390-7. PubMed ID: 24570378
[TBL] [Abstract][Full Text] [Related]
20. [Efficacy and safety of bevacizumab (BEV) plus chemotherapeutic agents in the treatment of metastatic colorectal cancer, mCRC].
Guo X; Liu TS; Yu YY; Zhou YH; Chen Y; Zhuang RY; Cui YH
Zhonghua Zhong Liu Za Zhi; 2013 Aug; 35(8):604-7. PubMed ID: 24314219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
